Home
HelpTest ID: AH50 Alternative Complement Pathway, Functional, Serum
Reporting Name
Alternative Complement Path Func, SUseful For
Investigation of suspected alternative pathway complement deficiency, atypical hemolytic uremic syndrome, C3 glomerulonephritis, and dense-deposit disease
Specimen Type
Serum RedOrdering Guidance
COM / Complement, Total, Serum and this test are the most appropriate primary assays to use as screening methods for complement deficiencies. Abnormal results in one or the other, neither or both assays will help direct further testing.
This test is rarely useful when ordered in isolation.
Specimen Required
Patient Preparation: Patient should be fasting.
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Collection Container/Tube: Red top (serum gel/SST are not acceptable)
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Collection Instructions:
1. Immediately after specimen collection, place the tube on wet ice.
2. After sample has clotted on wet ice, centrifuge at 4° C and aliquot serum into a plastic vial.
3. Freeze specimen within 30 minutes of centrifugation. Sample must be placed on dry ice if not frozen immediately.
NOTE: If a refrigerated centrifuge is not available, it is acceptable to use a room temperature centrifuge, provided the specimen is kept on ice before centrifugation, and immediately afterward, the serum aliquoted and frozen.
Specimen Minimum Volume
0.2 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Serum Red | Frozen | 14 days |
Reference Values
≥46% normal
Day(s) Performed
Monday, Thursday
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
86161
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| AH50 | Alternative Complement Path Func, S | 74520-8 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 88676 | Alternative Complement Path Func, S | 74520-8 |
Clinical Information
Complement proteins are components of the innate immune system. There are 3 pathways to complement activation:
1. The classical pathway
2. The alternative (or properdin) pathway
3. The lectin (or mannose-binding lectin, MBL) pathway
The total complement (CH50) assay (COM / Complement, Total, Serum) assesses the classical complement pathway including early components that activate the pathway in response to immune complexes (C1q, C2 and C4), as well as the terminal complement components (C3, C5, C6, C7, C8, C9) involved in the formation of the membrane attack complex (MAC). The CH50 assay will be abnormal if there are specific hereditary or acquired C1-C9 complement component deficiencies or if there is consumption of complement due to immune (or autoimmune) complexes.
This assay is a screening test for complement abnormalities in the alternative pathway. The alternative complement (AH50) pathway shares C3 and C5-C9 components but has unique early complement components designated factors D, B, and properdin, as well as control proteins factor H and factor I. This pathway can be activated by spontaneous hydrolysis of C3 or by microbial polysaccharides and does not require immune complex formation. Patients with disseminated infections with pyogenic bacteria in the presence of a normal CH50 may have a decreased AH50 due to hereditary or acquired deficiencies of the alternative pathway. Patients with deficiencies in the alternative pathway factors (D, B, properdin, H, and I) or late complement components (C3, C5-C9) are highly susceptible to recurrent Neisserial meningitis. The use of the CH50 and AH50 assays allow identification of the specific pathway abnormality.
Functional testing for complement pathways activity is indicated in the study of complement components deficiency, where testing serves as a first-tier screening, or in the study of complement dysregulation. Complement dysregulation is a general grouping of complement conditions where there is loss of control of the complement cascade with over-activation. In several cases, the complement system will attack the host and the over-activation of the complement cascade may cause disease.
Over-activation of the alternative pathway usually presents with renal function impairment, in rare conditions such as atypical hemolytic uremic syndrome and C3 glomerulopathies (dense deposit disease and C3 glomerulonephritis).
The use of complement inhibitor therapies such as eculizumab and ravulizumab will result in the blocking of C5. C5 is necessary for the AH50 test to progress until the formation of the MAC. Hence, in the presence of eculizumab or ravulizumab, AH50 results will be decreased or undetectable.
Interpretation
Absent complement alternative pathway (AH50) in the presence of a normal total hemolytic complement (CH50) suggests an alternative pathway component deficiency.
Normal AH50 with absent CH50 suggests an early (C1, C2, C4) classic pathway deficiency.
Absent AH50 and CH50 suggests a late (C3, C5, C6, C7, C8, C9) component deficiency or complement consumption.
Absent AH50 and CH50 in the presence of a normal C3 and C4 suggests a late (C5, C6, C7, C8, C9) component deficiency.
Normal CH50 and AH50 in the presence of recurrent infection and continued suspicion of complement deficiency, suggest testing for lectin pathway function.
Clinical Reference
1. Frank MM. Medical intelligence current concepts: complement in the pathophysiology of human disease. N Engl J Med. 1987;316(24):1525-1530. doi:10.1056/NEJM198706113162407
2. Thurman JM, Holers VM. Brief reviews: the central role of the alternative complement pathway in human disease. J Immunol. 2006;176(3):1305-1310. doi:10.4049/jimmunol.176.3.1305
3. Frank MM. Complement deficiencies. Pediatr Clin North Am. 2000;47(6):1339-1354. doi:10.1016/s0031-3955(05)70274-1
4. Go RS, Winters JL, Leung N, et al. Thrombotic microangiopathy care pathway: A consensus statement for the Mayo Clinic Complement Alternative Pathway-Thrombotic Microangiopathy (CAP-TMA) Disease-Oriented Group. Mayo Clin Proc. 2016;91(9):1189-1211. doi:10.1016/j.mayocp.2016.05.015
5. Willrich MAV, Andreguetto BD, Sridharan M, et al. The impact of eculizumab on routine complement assays. J Immunol Methods. 2018;460:63-71. doi:10.1016/j.jim.2018.06.010
Report Available
3 to 5 daysMethod Name
Enzyme-Linked Immunosorbent Assay (ELISA)
Forms
If not ordering electronically, complete, print, and send a Renal Diagnostics Test Request (T830) with the specimen.
mcl-tma